Coronavirus Disease 2019 and Emerging Lung Infections in the Immunocompromised Patient - 30/01/25

Doi : 10.1016/j.ccm.2024.10.015

Catia Cilloniz, PhD ^a,^b,^c,^{^{1
Present address. C/Paris 141, 5-3, 08036 Barcelona, Spain.}} , Antoni Torres, MD ^a,^b,^d,^⁎
^a Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Carrer del Rosselló, 149, Barcelona, Spain
^b Ciber de Enfermedades Respiratorias (Ciberes) Barcelona, Spain
^c Faculty of Health Sciences, Continental University, Av San Carlos 1980, Huancayo, Peru
^d Pulmonary Department, Hospital Clinic of Barcelona, Villarroel 170, Barcelona, Spain

^∗Corresponding author. C/ Villarroel 170, Barcelona 08036, Spain.C/ Villarroel 170Barcelona08036Spain

connectez-vous ou créez un compte

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Résumé

The immunocompromised are at higher risk of COVID-19 and lung infections, and these are associated with more severe presentations and greater risk of complication, increasing the risks of intensive care unit admission and poor outcomes. However, only limited high-quality data are available about the diagnosis and management of lung infections in this population, with many clinical trials and other large studies excluding the immunocompromised. Well-designed studies are needed to better understand the optimal diagnostic and management options to improve outcomes in the increasingly heterogeneous group of immunocompromised patients.

Le texte complet de cet article est disponible en PDF.

Keywords : COVID-19, Lung infection, Immunocompromised, Pneumonia